TNFRSF1A Human shRNA Lentiviral Particle (Locus ID 7132)

CAT#: TL308734V

TNFRSF1A - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

Product Images

GFP signal was observed under microscope at 48 hours after transduction of TL308734A virus into HEK293 cells. TL308734A virus was prepared using lenti-shRNA TL308734A and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of TL308734B virus into HEK293 cells. TL308734B virus was prepared using lenti-shRNA TL308734B and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL308734C] virus into HEK293 cells. [TL308734C] virus was prepared using lenti-shRNA [TL308734C] and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL308734D] virus into HEK293 cells. [TL308734D] virus was prepared using lenti-shRNA [TL308734D] and TR30037 packaging kit.

Specifications

Product Data

• Locus ID: 7132
• Synonyms: CD120a; FPF; p55; p55-R; p60; TBP1; TNF-R; TNF-R-I; TNF-R55; TNFAR; TNFR1; TNFR55; TNFR60
• Vector: pGFP-C-shLenti
• Format: Lentiviral particles
• RefSeq: NM_001065, NM_001346091, NM_001346092, NR_144351, NM_001065.1, NM_001065.2, NM_001065.3, BC010140, BC010140.2, NM_001065.4
• UniProt ID: P19438
• Summary: This gene encodes a member of the TNF receptor superfamily of proteins. The encoded receptor is found in membrane-bound and soluble forms that interact with membrane-bound and soluble forms, respectively, of its ligand, tumor necrosis factor alpha. Binding of membrane-bound tumor necrosis factor alpha to the membrane-bound receptor induces receptor trimerization and activation, which plays a role in cell survival, apoptosis, and inflammation. Proteolytic processing of the encoded receptor results in release of the soluble form of the receptor, which can interact with free tumor necrosis factor alpha to inhibit inflammation. Mutations in this gene underlie tumor necrosis factor receptor-associated periodic syndrome (TRAPS), characterized by fever, abdominal pain and other features. Mutations in this gene may also be associated with multiple sclerosis in human patients. [provided by RefSeq, Sep 2016]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).